Hims & Hers Stock Confirms Uptrend as JPMorgan Backs GLP-1 Strategy
Hims & Hers Health is staging a strong recovery as analyst upgrades, regulatory optimism, and its GLP-1 weight-loss strategy drive renewed..
Quick overview
- Hims & Hers Health is experiencing a strong recovery driven by analyst upgrades and a focus on GLP-1 weight-loss treatments.
- JPMorgan's 'Overweight' rating and $35 price target have boosted investor confidence, leading to a nearly 10% surge in stock prices.
- The company's strategic shift towards fully approved treatments is expected to create temporary revenue impacts but is viewed positively for long-term sustainability.
- Regulatory optimism and expanding international efforts further support Hims & Hers' growth outlook despite short-term challenges.
Hims & Hers Health is staging a strong recovery as analyst upgrades, regulatory optimism, and its GLP-1 weight-loss strategy drive renewed investor interest.
Stock Gains on JPMorgan Confidence
Hims & Hers Health shares surged nearly 10% after JPMorgan initiated coverage with an “Overweight” rating and a $35 price target. The upgrade reflects growing confidence in the company’s improving fundamentals and expanding growth drivers.
JPMorgan highlighted the company’s strategic direction, particularly its push into the fast-growing weight-loss market. The price target implies further upside, reinforcing the view that Hims & Hers may be entering a new phase of growth after a prolonged decline.
Stock Rebound Signals Shift in Sentiment
The rally marks a notable turnaround for the stock, which had struggled in previous months. Shares climbed sharply, extending gains from the prior week and signaling renewed investor confidence.
This rebound is largely driven by improving sentiment around the company’s long-term strategy. Investors are increasingly focusing on its positioning within the weight-loss and telehealth sectors, where demand continues to grow rapidly.
GLP-1 Strategy Driving Growth
At the center of the recovery is Hims & Hers’ expansion into GLP-1 weight-loss treatments. Through its partnership with Novo Nordisk, the company is offering FDA-approved medications such as Wegovy and Ozempic.
Demand for these treatments is accelerating, with management indicating that prescriptions for Wegovy could exceed 100,000 per month. This shift toward branded, regulated medications strengthens Hims’ credibility and positions it more competitively within the healthcare market.
Regulatory Tailwinds Support Expansion
Regulatory developments are adding another layer of optimism. The U.S. Food and Drug Administration is reviewing peptide regulations, potentially easing restrictions on certain compounds.
This move could open new opportunities for telehealth platforms to expand their offerings. Support from Robert F. Kennedy Jr. has further fueled expectations of a more favorable regulatory environment. Hims has already taken steps to prepare for this shift by acquiring a peptide manufacturing facility in California.
Rebound Gains Strength
Hims & Hers Health stock has been under pressure since October, but sentiment has shifted in recent weeks. After an initial rebound in early March, the stock is gaining further traction, rising around 35% last week and pushing above the $30 level this week.
HIMS Chart Daily – The 100 SMA Turned into Support
From a technical perspective, HIMS has broken above its 50-day moving average and the 100 SM A(green) which has turned into support now, signaling improving short- to medium-term momentum. However, it remains below the 200-day moving average near $38, suggesting that longer-term resistance still caps the upside.
Strategic Shift Brings Short-Term Pressure
Earlier in 2026, Hims & Hers announced a strategic pivot toward fully approved treatments, reducing reliance on compounded alternatives. While this aligns with regulatory trends, it is expected to create a temporary revenue impact of around $65 million due to delays in shipments.
Despite this near-term pressure, the move is viewed positively by investors as it strengthens compliance and supports long-term sustainability.
Growth Outlook and Market Position
Beyond weight-loss treatments, Hims & Hers continues to expand internationally, supported by acquisitions such as ZAVA and Livewell. These efforts highlight the company’s ambition to scale globally and diversify its revenue streams.
The recent rally also reflects improving sentiment after earlier concerns, including data security issues. Combined with potential short-covering activity, these factors have contributed to the stock’s sharp recovery.
Overall, Hims & Hers appears to be regaining momentum, with its GLP-1 strategy and regulatory tailwinds positioning it for continued growth, even as it navigates short-term challenges.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
Save